Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation
whenever the CHADS2VASC score is superior or equal to 2. As there are no specific guidelines
for the hemodialysis patients with atrial fibrillation, the general guidelines apply.
However, several retrospective studies suggest that these patients do not benefit from the
oral anticoagulation regarding the risk of stroke and may even experience more bleedings and
The aim of this prospective study is to prospectively compare the hemorrhagic and thrombotic
risks of oral anticoagulation in comparison with no anticoagulation in hemodialysis patients
with atrial fibrillation.